Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Coulter, Jonathan B., Easwaran, Hariharan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Primer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138788/
https://www.ncbi.nlm.nih.gov/pubmed/37104249
http://dx.doi.org/10.1371/journal.pbio.3002081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138788/
https://www.ncbi.nlm.nih.gov/pubmed/37104249
http://dx.doi.org/10.1371/journal.pbio.3002081

Ejemplares similares